Lowest Price Guaranteed From USD 2,199
Published
June 2015
Pages
360
View Count
9145
Example Insights
An updated edition is available at the following link
Report Description
Injectable drug delivery systems have traversed a long way from conventional syringes with vials to prefilled syringes, auto-injectors, pen injectors and needle free systems. These modern devices have become preferred devices for parenteral administration of drugs, mainly used for treatment of chronic conditions requiring patients to self-administer medication several times a week.
The origins of prefilled syringes can be traced back to early 1980s when Sanofi and Rhone Poulenc-Rorer (Sanofi-Aventis) introduced syringes as drug delivery devices for heparins in Europe. These have been around for more than three decades and are used in all major therapeutic classes for injectable drug formulations. Owing to their numerous benefits over conventional delivery systems and the growing application areas, prefilled syringes have now become indispensable in the medical fraternity. This is evident from our research during which we identified a large number of instances where prefilled syringes are being used to administer vaccines, anticoagulants, multiple sclerosis drugs, anti-arthritic drugs, anti-anaemic drugs and drugs from several other classes. Further, these syringes are also being used as primary drug containers in pen and auto-injectors. In addition, prefilled diluent syringes and flush syringes are also increasingly finding wider adoption. With pharma companies viewing prefilled syringes as a potent life cycle management tool, the pipeline is rich and growing rapidly.
The rising demand has also driven the manufacturers to introduce improvements in technology related to the material of prefilled syringes and lubrication (to reduce leachables and extractables). These developments will aid an increasing number of biologic drugs to reach the market. Additionally, the companies have developed multi-chamber prefilled syringes for use with lyophilised drugs. In our research, we have looked at how these developments and other factors are shaping the market and discussed the factors creating opportunities for various stakeholders in the market.
Scope of the Report
The ‘Prefilled Syringes Market (3rd Edition)’ report provides a comprehensive analysis of the state of prefilled syringes market. Starting with the basic introduction to prefilled syringes, their origin, components and manufacturing material, this report talks about needlestick injuries and looks at the safety laws and legislations across major regional markets for prefilled syringes. A key objective of the report is to enumerate various prefilled syringe systems available in the market, drugs available in these syringes and the corresponding market potential across different geographical regions. We have discussed various historical/likely future trends which have shaped/will shape the US, European, Japanese, Chinese, Indian and rest of the world markets. We have also included a detailed overview of biologics and biosimilars, one of the primary growth drivers of this market.
The study focuses on analysing the existing market size and potential future growth of these drug delivery devices across different drug therapeutic classes and regions. The forecast, over the next ten years, has been presented both in terms of volume (number of units) and value (USD billion). It takes into account the likely price variation which will occur as a result of mass adoption and increased competition. Owing to uncertainty surrounding the adoption of prefilled syringes in newer drug classes (which are currently in pipeline); we have also done a multi-variate sensitivity analysis to understand the various market growth scenarios.
In an effort to identify existing gaps and future opportunities, we have discussed the leading global prefilled syringe manufacturers in the industry, analysed their product portfolio and the likely future developments driven by these companies. We have put special emphasis and provided details on local manufacturers which are very well positioned to take advantage of the emerging big home consumer markets. In addition, we have profiled some important prefilled syringe component manufacturers as well as manufacturers of self-injection systems that use prefilled syringes as primary drug container.
The market forecasts across different segments and regions have been presented till 2025. 2014 is the base year; actual figures have been sourced and analysed from publicly available information. Unless otherwise specified, all figures are presented in USD.
Contents
Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of prefilled syringes market.
Chapter 3 provides a general overview of prefilled syringes including their origin, components, types and manufacturing material. We have listed the major prefilled syringes currently available and presented a detailed market landscape. The chapter also discusses the technological advancements that have led to the evolution of the industry over the last several years.
Chapter 4 highlights the issue of needlestick injuries and various preventive laws worldwide which have put the focus on safety features in prefilled syringes.The chapter also discusses various manufacturers of safety systems including add-on devices and integrated safety prefilled syringes.
Chapter 5 highlightsthe key growth drivers of prefilled syringes market. These include the growing trend of self-injection, rise in chronic diseases, changing patient demographics and growth of biologics.
Chapter 6 highlights the leading therapeutic drug classes available in prefilled syringes. It also provides a list of top nine drugs in prefilled syringes with detailed case studies on Humira, Enbrel and Copaxone. For each therapeutic class, we have identified the drugs available in prefilled syringes and estimated patent expiry; we have also looked at the biosimilars currently in development.
Chapter 7 details the recent technological developments and their applications in prefilled syringes market focusing on syringes being manufactured for lyophilised drugs in dual / multi chambered system for drug reconstitution.
Chapter 8 provides profiles of the key manufacturers of prefilled syringes. Each company profile includes information on financial performance, geographical presence, marketed devices, recent developments and an informed future outlook. Key players covered in this section include (in alphabetical order) Aguettant, Becton Dickinson, Gerresheimer, Nipro Corporation, Nuova Ompi, SCHOTT, Unilife, Vetter Pharma and West Pharmaceuticals.
Chapter 9 highlights various prefilled syringe component manufacturers and their product portfolio. Key players covered in this section include Aptar Stelmi, Datwyler and West Pharmaceuticals.
Chapter 10 discusses detailed profiles of major pen and auto-injector manufacturers which use prefilled syringes as primary drug container providing information on their financial performance, product portfolio and recent developments. Key players covered in this section include (in alphabetical order) Becton Dickinson, Bespak, DALI Medical, Future Injection Technologies, Owen Mumford, SHL Group, Unilife, West Pharmaceuticals and Ypsomed.
Chapter 11 provides the SWOT analysis of prefilled syringes market giving strategic insights on the major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that can negatively impact the growth.
Chapter 12 analyses the regional markets (the US, Europe, China, Japan, India and RoW) for prefilled syringes. For each region, the chapter focuses on the market size and various technological, commercial and regulatory details; in addition to the global players which have been profiled in earlier sections, this chapter includes profiles of the key regional players in Chinese, Japanese and Indian markets.
Chapter 13 provides a detailed description of the likely evolution of prefilled syringes market. We have adopted a detailed ‘top down’ approach, backed by robust data and credible inputs from primary research, to identify the likely size of the market, both in terms of volume (number of units) and value (in USD billion).
Chapter 14 is a collection of interview transcripts. For the purposes of our study, we contacted a number of stakeholders in order to ascertain the key strategic initiatives and future roadmap of the industry.
Chapter 15 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.
Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 17 is an appendix, which provides a list of companies and organisations mentioned in this report.
PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION TO PREFILLED SYRINGES
3.1. Chapter Overview
3.2. History of Prefilled Syringes
3.3. Benefits of Prefilled Syringes over Traditional Injectable Devices
3.3.1. Benefits for Healthcare Professionals and End Users
3.3.2. Benefits for Manufacturers
3.3.3. Shift of Existing Formulations to Prefilled Syringes
3.4. Prefilled Syringe Components
3.5. Classification of Prefilled Syringes
3.5.1. Manufacturing Material of Barrel
3.5.2. Glass: Historical Material of Choice
3.5.2.1. Limitations of Glass Prefilled Syringes
3.5.2.2. Addressing the Limitations of Glass Prefilled Syringes
3.5.2.3. Advantages of Plastic Prefilled Syringes
3.5.2.4. Slow Adoption of Plastic Prefilled Syringes
3.5.2.5. Factors Likely to Drive the Use of Plastic Prefilled Syringes
3.5.3. Single-Chamber and Dual-Chamber
3.5.4. Type of Needle
3.5.5. Type of Processing
3.6. Critical Attributes of a Prefilled Syringe Design
3.7. Prefilled Syringe Systems Available in the Market
3.7.1 Glass Prefilled Syringes
3.7.2 Plastic Prefilled Syringes
3.8. Technological Developments in Prefilled Syringes
4. NEEDLESTICK INJURIES
4.1. Chapter Overview
4.2. Incidence and Cost Burden
4.3. Government Legislation for Needlestick Injury Prevention
4.4. Safety Mechanism Used by Prefilled Syringe Manufacturers
4.4.1. Safety Systems: Add-on Devices
4.4.2. Safety Systems: Integrated Devices
5. GROWTH DRIVERS
5.1. Chapter Overview
5.2. Increase in Number of Self-injecting Patients
5.3. Increase in Incidence of Chronic Diseases
5.4. Changing Patient Demographics
5.5. Growth of Biologics and Biosimilars
5.6. Changing Pharmaceutical Strategies Driving Demand for Prefilled Syringes
5.7. Auto-Injectors / Pen-Injectors
5.7.1. Convergence of Prefilled Syringes with Auto-injectors
5.7.2. Pen-injectors vs. Auto-injectors
6. PRODUCTS AVAILABLE IN PREFILLED SYRINGES
6.1. Chapter Overview
6.2. Drugs Approved in Prefilled Format in 2013-2015
6.3. Leading Drugs (By Sales) in Prefilled Format, 2014
6.3.1. Case Study: Humira (Adalimumab), AbbVie/Eisai
6.3.1.1. Indications and Dosage Forms
6.3.1.2. Humira: Launched in Prefilled Syringe
6.3.2. Case Study: Enbrel (Etanercept), Amgen/Pfizer/Takeda
6.3.2.1. Indications and Dosage Forms
6.3.2.2. Enbrel: Move from Vial to Syringes
6.3.3. Copaxone (Glatiramer Acetate), Teva Pharmaceuticals
6.3.3.1. Indications and Dosage Forms
6.3.3.2. Copaxone: Move from Vial to Syringes
6.4. Other Drugs Available in Prefilled Format, 2014
6.5. Pipeline Products
6.6. Drugs Available by Therapeutic Classes
6.6.1. Anti-rheumatics
6.6.1.1. Approved Injectables
6.6.1.2. Biosimilars
6.6.2. Multiple Sclerosis (MS)
6.6.2.1. Approved Injectables
6.6.2.2. Biosimilars
6.6.3. Anti-virals, 2015
6.6.3.1. Approved Injectables, 2015
6.6.3.2. Biosimilars
6.6.4. Anticoagulants, 2015
6.6.4.1. Approved Injectables, 2015
6.6.4.2. Biosimilars/Generics
6.6.5. Vaccines Market, 2015
6.6.6. Anti-Diabetes Market, 2015
6.6.6.1. Insulin Market, 2015
6.6.6.2. Approved Injectables
6.6.6.3. Biosimilars
6.7. Contrast Agents Available in Prefilled Syringes
7. RECENT DEVELOPMENTS AND APPLICATIONS OF PREFILLED SYRINGES
7.1. Chapter Overview
7.2. Prefilled Syringes for Lyophilised Drugs
7.2.1. Prefilled Diluent Syringes
7.2.1.1. Lyophilised Drugs Available in Prefilled Diluent Syringe Systems
7.2.2. Dual/Multi-Chamber Syringes
7.2.2.1. Lyophilised Drugs Available in Dual/Multi-Chamber Prefilled Syringe
7.2.2.2. Prefilled Dual-Chambered Pen Injectors for Lyophilised Drugs
7.2.3. Prefilled Reconstitution Systems for Lyophilised Drugs
8. MANUFACTURERS OF PREFILLED SYRINGE
8.1. Chapter Overview
8.2. Mapping the Competitive Landscape
8.3. Leading Global Prefilled Syringes Manufacturers
8.4. Becton Dickinson (BD)
8.4.1 Company Overview
8.4.2. Financial Performance, 2010-2014
8.4.3. Glass Prefilled Systems
8.4.3.1. BD Hypak Syringe System
8.4.3.2. Luer Products
8.4.3.3. Staked Needle Products
8.4.3.4. BD Neopak Syringe System
8.4.4. Plastic Prefilled Systems
8.4.4.1. BD Sterifill Syringe Systems
8.4.5. Other Prefilled Delivery Systems
8.4.5.1. BD Uniject
8.4.5.2. BD Soluvia
8.4.6. BD Prefilled Technology Solutions
8.4.7. Recent Developments
8.4.7.1. Deals and Agreements
8.4.7.2. Expanding Prefilled Syringe Portfolio
8.4.7.3. Entering the Generic Business
8.4.8. Future Outlook
8.5. Gerresheimer
8.5.1. Company Overview
8.5.2. Financial Performance, 2010- 2014
8.5.3. Glass Prefilled Systems
8.5.3.1. Gx Glass Syringes
8.5.4. Plastic Prefilled Systems
8.5.4.1. ClearJect Plastic Syringes
8.5.5. Self-Injection Devices
8.5.6. Prefilled Technology Solutions
8.5.7. Recent Developments
8.5.7.1. Expansion of Product Portfolio
8.5.7.2. Expansion of Manufacturing Capacity for RTF Syringes
8.5.7.3. Medical Plastic Systems Capacity Expansion
8.5.7.4. Growing Interest in Emerging Economies
8.5.8. Future Outlook
8.6. Nipro Corporation (acquired MGlas AG)
8.6.1. Company Overview
8.6.2. Financial Performance, 2010-2014
8.6.3. Glass Prefilled Systems
8.6.4. Plastic Prefilled Systems
8.6.5. Recent Developments
8.6.6. Future Outlook
8.7. SCHOTT
8.7.1. Company Overview
8.7.2. Financial Performance, 2014
8.7.3. Glass Prefilled Systems
8.7.3.1. syriQ (previously Forma 3s) Glass Syringes
8.7.3.2. syriQInJentle Syringes
8.7.4. Plastic Prefilled Systems
8.7.4.1. TopPac Polymer Syringes
8.7.5. Recent Developments
8.7.5.1. TopPac Syringe System for Sensitive Drugs (SD)
8.7.5.2. TopPac Syringe System for Highly Viscous Drugs
8.7.5.3. TopPac 20 ml Syringe System for Infusion Therapy
8.7.5.4. Rebranding of the Glass PFS
8.7.5.5. Looking To Grow in the Pharma EmergingMarkets (Brazil, China, India, Indonesia and Russia)
8.7.5.6. Production Facility in the US and EU Likely to Provide Advantage
8.7.6. Future Outlook
8.8. Nuova Ompi
8.8.1. Company Overview
8.8.2. Glass Prefilled Systems
8.8.2.1. EZ-fill Syringes
8.8.3. Recent Developments
8.8.3.1. New Corporate Branding
8.8.3.2. Capacity Expansion Across the Glass Division
8.9. Other Prefilled Syringe Manufacturers
8.10. West Pharmaceutical Services, Inc.
8.10.1. Company Overview
8.10.2. Financial Performance, 2010 - 2014
8.10.3. Plastic Prefilled Systems
8.10.3.1. Daikyo Crystal Zenith (CZ) RU PFS
8.10.4. Drug Reconstitution Systems
8.10.5. Prefilled Technology Solutions
8.10.6. Recent Developments
8.10.6.1. Advancing the Growth of CZ Syringes
8.10.6.2. Looking To Grow in the Pharmerging Markets (Brazil, China, India)
8.10.6.3. Manufacturing Expansion
8.10.7. Future Outlook
8.11. Unilife Corporation
8.11.1. Company Overview
8.11.2. Financial Performance, 2011- 2014
8.11.3. Glass PFS
8.11.3.1. Unifill Syringes
8.11.3.2. EZ-Mix Syringes
8.11.4. Wearable Injector Platform
8.11.5. Ocular Delivery Systems
8.11.6. Novel Delivery Systems
8.11.7. Supply Agreements
8.11.7.1. Partnership with AbbVie
8.11.7.2. Partnership with Global Pharma Company
8.11.7.3. Partnership with Novartis
8.11.7.4. Partnership with Hikma
8.11.7.5. Partnership with Sanofi
8.11.7.6. Partnership with Biodel
8.11.8. Recent Developments
8.11.8.1. Expansion
8.11.8.2. Fundings
8.11.9. Future Outlook
8.12. Vetter Pharma
8.12.1. Company Overview
8.12.2. Lyo-Ject Glass PFS
8.12.3. Recent Developments
8.12.3.1. Capacity Expansion
8.12.3.2 Collaboration with West Pharmaceuticals
8.12.4. Future Outlook
8.13. Aguettant
8.13.1. Company Overview
8.13.1.1. Aguettant Prefilled Syringe
8.13.1.2. Aguettant Self Injector Pen
8.13.2. Recent Developments
9. PFS COMPONENT MANUFACTURERS
9.1. Chapter Overview
9.2. West Pharmaceutical Services, Inc.
9.2.1. PFS Components
9.2.1.1. Plungers
9.2.1.2. Needle Shield and Tip Cap
9.2.1.3. Backstops
9.2.2. Manufacturing of PFS Components
9.3. Datwyler
9.3.1. Financial Performance, 2010- 2014
9.3.2. PFS Components
9.3.2.1. Plungers
9.3.2.2. Needle Shields and Tip Caps
9.3.3. Manufacturing of PFS Components
9.4. Aptar Stelmi
9.4.1. Financial Performance,2014
9.4.2. PFS Components
9.4.2.1. Plungers
9.4.2.2. Needle Sheilds
9.4.2.3. Tip Caps
9.4.2.4. Stoppers
10. GLOBAL PEN AND AUTO-INJECTOR MANUFACTURERS
10.1. Chapter Overview
10.2. Ypsomed Holding AG
10.2.1. Company Overview
10.2.2. Financial Performance, 2010- 2014
10.2.3. Product Portfolio
10.2.3.1. Auto-Injectors
10.2.4. Recent Developments
10.2.4.1. Geographical Expansion
10.2.4.2. Collaborations
10.2.5. Development Strategy
10.3. Scandinavian Health Limited (SHL) Group
10.3.1. Company Overview
10.3.2. Product Portfolio
10.3.2.1. Auto-injectors
10.3.3. Recent Developments
10.3.3.1. Capacity Expansion
10.3.3.2. Collaborations
10.3.4. Development Strategy
10.4. Bespak
10.4.1. Company Overview
10.4.2. Financial Performance, 2010- 2014
10.4.3. Product Portfolio
10.4.3.1. Auto-injectors
10.4.4. Recent Developments
10.4.4.1. Collaborations
10.4.5. Future Outlook
10.5. Owen Mumford
10.5.1. Company Overview
10.5.2. Product Portfolio
10.5.2.1. Auto-injectors
10.6. DALI Medical Devices/Elcam Medical
10.6.1. Company Overview
10.6.2. Product Portfolio
10.6.2.1. DALI Products
10.6.2.2. Elcam Products
10.7. Future Injection Technologies
10.7.1. Company Overview
10.7.2. Product Portfolio
10.8. Other Companies Offering Pen and Auto Injectors
10.8.1. Unilife
10.8.2. West Pharmaceutical Services
10.8.3. Becton Dickinson
11. SWOT ANALYSIS
11.1. Chapter Overview
11.2. Strengths
11.2.1. Ease of Use
11.2.2. Elimination of Medication Errors
11.2.3. High Incidence of Blood-borne Pathogen Transmission
11.2.4. Economic Advantages
11.2.5. Life Cycle Management
11.3. Weaknesses
11.3.1. Manufacturing Complexities
11.3.2. Elevated Packaging Costs
11.3.3. Product Stability
11.3.4. Air Bubbles During Filling
11.4. Opportunities
11.4.1. Use of Prefilled Syringes in Advanced Delivery Devices
11.4.2. Innovation in Prefilled Syringes to Address Needlestick Injuries
11.4.3. Geographic Expansion
11.4.4. Useful in Vaccination Programmes
11.5. Threats
11.5.1. Material Compatibility Issues
11.5.2. Recall of Prefilled Syringes
11.5.3. Alternative Drug Delivery Devices
12. LEADING REGIONAL MARKETS FOR PREFILLED SYRINGE SYSTEMS, 2015 – 2025
12.1. Chapter Overview
12.2. The US Market for Prefilled Syringes, 2014
12.2.1. Prefilled Syringes are Combination Products
12.2.2. Regulation of Combination Products in the US
12.2.3. Regulatory Approval of Prefilled Syringes in the US
12.2.4. Trends in the US Prefilled Syringes Market
12.3. European Market for Prefilled Syringes, 2014
12.3.1. Combination Products in Europe
12.3.2. Regulatory Approval of Prefilled Syringes in Europe
12.3.3. Trends in the European Prefilled Syringe Market
12.3.3.1. Europe is the Preferred Destination for Manufacturing Prefilled Syringes
12.4. The Chinese Market for Prefilled Syringes, 2014
12.5. Chinese Prefilled Syringe Manufacturers
12.5.1. Shandong Weigao Group Pharmaceutical Packaging Company Ltd.: First Registered Manufacturer Of PFS In China Since 2005
12.5.1.1. Financial Performance, 2014
12.5.1.2. WeGo: Glass PFS
12.5.2. Shandong Zibo Minkang Pharmaceutical Packing Co., Ltd.
12.5.3. Shandong Pharmaceutical Glass Co., Ltd.
12.5.4. YangZhong Wealth Metal Co., Ltd.
12.5.5. Youlyy Industrial Co., Ltd.
12.6. The Japanese Market for Prefilled Syringes
12.6.1. Regulation of Combination Products in Japan
12.6.2. Primary Pharmaceutical Packaging Market in Japan
12.6.3. State of the Market: Drugs and Companies
12.7. Japanese Prefilled Syringe Manufacturers
12.7.1. Terumo Corporation: Growing Y-o-Y Sales of Plastic PFS Indicates an Increasing Trend of a Shift from Glass PFS
12.7.1.1. Company Overview
12.7.1.2. Financial Performance, 2010- 2014
12.7.1.3. Plajex: Plastic PFS
12.7.1.4. Safety Devices: Add-On Devices
12.7.2. Taisei Kako Co., Ltd.: Sales Tie-Up With Gerresheimer Bunde Has Facilitated Availability Of Plastic PFS To Worldwide Locations
12.7.2.1. Company Overview
12.7.2.2. VF-Syringe Glass PFS
12.7.2.3. ClearJect Plastic Prefilled Syringes
12.7.2.4. Fulject Plastic Prefilled Syringes
12.7.3. ARTE CORPORATION: Manufacturing Single And Dual-Chambered PFS
12.7.3.1. Company Overview
12.7.3.2. Arte Prefillable Syringes
12.7.4. J.O. Pharma Co., Ltd. (Subsidiary of Otsuka Holdings Co., Ltd): Continually Expanding To Meet The Growing Demand For PFS
12.8. Indian Market for Prefilled Syringes, 2014
12.9. Indian Prefilled Syringe Manufacturers
12.9.1. Roselabs Group: First Indian Company Manufacturing and Formulating Under One Roof
12.9.1.1. Company Overview
12.9.1.2. Rose-Fill Glass Prefilled Systems
12.9.1.3. Rose-Fill Plastic Prefilled Systems
12.9.1.4. Recent Developments
12.10 Indonesian Market for Prefilled Syringes, 2014
13. GLOBAL PREFILLED SYRINGES MARKET FORECAST, 2015 - 2025
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Global Market Size and Forecast
13.3.1. Prefilled Syringes for Vaccines
13.3.2. Prefilled Syringes for Drugs
13.3.2.1. Prefilled Syringes for Anticoagulants
13.3.2.2. Prefilled Syringes for Diabetes
13.3.2.3. Prefilled Syringes for Multiple Sclerosis Drugs
13.3.2.4. Prefilled Syringes for Anti-Arthritic Drugs
13.3.2.5. Prefilled Syringes for Anti-Anaemic Drugs
13.3.2.6. Prefilled Syringes for Other Drug Classes
13.3.3. Prefilled Diluent Syringes, Prefilled Flush Syringes and Prefilled Syringes for Contrast Agents
13.3.4. Overall Global Market Size
13.4. Regional Market Size and Forecast: US, Europe, Asia Pacific and Rest of the World
14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. West Pharmaceutical Services, Inc.
14.3. Oval Medical Technologies
14.4. Revolutions Medical
15. CONCLUSION
15.1. The Shift from Vials to Prefilled Syringes
15.2. Plastic Syringes to Outperform Glass Syringes
15.3. Consolidated Market with Five Established Players; New Entrants Driving Innovation
15.4. Growth of Biologics, Rising Trend of Self-Medication and Many Other Factors will Fuel the Growth
15.5. Slow Growth Expected Over the Coming Decade
15.6. Despite Being Full of Opportunities, Challenges Remain
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS
Figure 2.1 Market Evolution: 2015, 2020, 2025 (Number of Units)
Figure 2.2 Market Landscape: Geographical Trends
Figure 3.1 Glass Prefilled Syringes: Advantages and Disadvantages
Figure 3.2 Plastic Prefilled Syringes: Advantages and Disadvantages
Figure 3.3 Critical Design Parameters of Prefilled Syringes
Figure 3.4 Prefilled Syringes: Market Landscape by Manufacturer
Figure 3.5 Technological Evolutions of Prefilled Syringes
Figure 5.1 Global Prevalence of Diabetes: Distribution by Countries, 2013 (Million,%)
Figure 5.2 Numbers of Biologics Approved by the USFDA, 2009-2015
Figure 5.3 Top Selling Biologics: Estimated Patent Expiry
Figure 6.1 Sales of Leading Drugs Available in Prefilled Syringes, 2014 (USD Million)
Figure 6.2 Humira: Approval Timeline for Various Indications in the US & EU
Figure 6.3 Humira: Approval Timeline for Various Dosage Forms in the US & EU
Figure 6.4 Humira: Global Sales, 2003-2014 (USD Million)
Figure 6.5 Enbrel: Approval Timeline for Various Indications in the US & EU
Figure 6.6 Enbrel: Approval Timeline for Various Dosage Forms in the US & EU
Figure 6.7 Enbrel: US & Canada Sales, 2002-2014 (USD Million)
Figure 6.8 Enbrel: Outside US and Canada (EU, Japan) Sales, 2010-2014 (USD Million)
Figure 6.9 Copaxone: Sales, 2001-2014 (USD Million)
Figure 6.10 Copaxone: Unit Sales, 2000-2008: Distribution by Vials and Prefilled Syringes (Million)
Figure 6.11 Numbers of Biosimilars in Development for Anti-Rheumatics
Figure 6.12 Numbers of Biosimilars in Development for Multiple Sclerosis Drugs
Figure 6.13 Numbers of Biosimilars in Development for Anti-Virals
Figure 6.14 Numbers of Biosimilars in Development for Anticoagulants
Figure 6.15 Numbers of Biosimilars in Development for Anti-Diabetes
Figure 8.1 Glass PFS: Product Landscape Analysis
Figure 8.2 Polymer PFS: Product Landscape Analysis
Figure 8.3 Becton Dickinson Medical: Sales, 2010-2014 (USD, Billion)
Figure 8.4 Becton Dickinson Medical: Sales by Sub-Segments, 2014 (USD Billion, %)
Figure 8.5 Gerresheimer: Sales, 2010-2014 (EUR Million)
Figure 8.6 Gerresheimer: Sales by Business Divisions, 2014 (EUR Million, %)
Figure 8.7 Gerresheimer: Sales by Region, 2011-2014 (EUR Million)
Figure 8.8 Nipro Corporation: Sales, 2010-2014 (YEN Billion)
Figure 8.9 Nipro Corporation: Sales by Business Divisions, FY 2013/14 (YEN Billion, %)
Figure 8.10 Nipro Corporation: Global Sales by Region, FY 2013/14 (YEN Billion, %)
Figure 8.11 Nipro Corporation: Sales by Domestic Market, 2010-2014 (YEN Billion)
Figure 8.12 SCHOTT: Sales, FY 2012/13- FY2013/14 (EUR Million)
Figure 8.13 SCHOTT: Sales by Business Divisions, FY 2013/14 (EUR Million, %)
Figure 8.14 SCHOTT: Sales by Region, FY 2013/14 (EUR Million, %)
Figure 8.15 West Pharmaceutical Services: Sales, 2010-2014 (USD Million)
Figure 8.16 West Pharmaceutical Services: Sales by Business Divisions, 2014 (USD Million, %)
Figure 8.17 West Pharmaceutical Services: Delivery Systems Sales, 2010-2014 (USD Million)
Figure 8.18 West Pharmaceutical Services: Sales by Domestic Market, 2010-2014 (USD Million)
Figure 8.19 West Pharmaceutical Services: Global Sales by Region, 2014 (USD Million, %)
Figure 8.20 Unilife Corporation: Sales, FY 2010/11–2013/14 (USD Million)
Figure 9.1 Datwlyer Group: Sales, 2010-2014 (CHF, Million)
Figure 9.2 Datwlyer Group: Sales by Business Divisions, 2014 (CHF, Million)
Figure 9.3 Aptar Stelmi: Sales by Business Divisions, 2014 (USD, Million)
Figure 10.1 Ypsomed Sales, 2010-2014 (CHF Million)
Figure 10.2 Ypsomed: Sales by Business Divisions, FY 2014/15 (CHF Million, %)
Figure 10.3 Ypsomed: Cartridge Based Pen-Injectors
Figure 10.4 Ypsomed: Cartridge Based Dual Chamber Pen-Injectors
Figure 10.5 Ypsomed: Prefilled Syringe or Cartridge Based Auto-Injectors
Figure 10.6 SHL Medical: Cartridge Based Systems
Figure 10.7 SHL Medical: Prefilled Syringe Based Auto-Injectors
Figure 10.8 Bespak: Sales, 2009-2013 (GBP, Million)
Figure 10.9 Bespak Injectables: Cartridge Based Systems
Figure 10.10 Bespak: Lila Platform Products
Figure 10.11 Bespak Injectables: Prefilled Syringe Based Auto-Injectors
Figure 10.12 Owen Mumford: Cartridge-Based Injection Pens
Figure 10.13 Owen Mumford: Prefilled Syringe Based Auto-Injectors
Figure 10.14 DALI: Auto-injector Product Portfolio
Figure 10.15 Elcam Medical: Auto-injector Product Portfolio
Figure 10.16 Future Injection Technologies: Product Portfolio
Figure 10.17 Becton Dickinson: Cartridge Based Systems
Figure 11.1 Common Medication Errors (%)
Figure 11.2 Common Sources of Medication Errors (%)
Figure 11.3 Prefilled Syringe Recalls, 2003-2015: Distribution by Type of Issue
Figure 12.1 The US Vaccines Market: By Type of Packaging (%)
Figure 12.2 European Vaccines Market: By Type of Packaging (%)
Figure 12.3 Domestic Prefilled Syringe Manufacturers in China: Annual Production Capacities, 2012 (Million Units)
Figure 12.4 Shandong Weigao: Prefilled Syringes Revenue (RMB Million), 2010-2014
Figure 12.5 Shandong Weigao: Revenue by Product Category (RMB Million, %), 2014
Figure 12.6 Japanese Prefilled Syringes Market: By Material of Barrel (%)
Figure 12.7 Terumo Corporation: Sales, 2010 - 2014 (Yen Billion)
Figure 12.8 Terumo Corporation: Sales by Business Divisions, FY 2014/15 (YEN Billion, %)
Figure 12.9 Terumo Corporation: Sales by Region, FY 2014/15 (YEN Billion, %)
Figure 13.1 Prefilled Syringes Price Curve, 2015 – 2025 (USD per unit)
Figure 13.2 Prefilled Syringes for Vaccines, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Figure 13.3 Prefilled Syringes for Vaccines, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
Figure 13.4 Prefilled Syringes for Anticoagulants, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Figure 13.5 Prefilled Syringes for Anticoagulants, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
Figure 13.6 Prefilled Syringes for Diabetes, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Figure 13.7 Prefilled Syringes for Diabetes, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
Figure 13.8 Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Figure 13.9 Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
Figure 13.10 Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Figure 13.11 Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
Figure 13.12 Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Figure 13.13 Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
Figure 13.14 Prefilled Syringes for Other Drug Classes, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Figure 13.15 Prefilled Syringes for Other Drug Classes, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
Figure 13.16 Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Figure 13.17 Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
Figure 13.18 Global Prefilled Syringes, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Figure 13.19 Global Prefilled Syringes, Units Growth by Category, 2015 - 2025 (Base Scenario, USD Million)
Figure 13.20 Global Prefilled Syringes, Sales Forecasted, 2015 - 2025 (Base Scenario, USD Million)
Figure 13.21 Global Prefilled Syringes, Sales Growth by Category, 2014 - 2024 (Base Scenario, USD Million)
Figure 13.22 Regional Prefilled Syringes, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Figure 13.23 Regional Prefilled Syringes, ForecastedSales, 2015 - 2025 (Base Scenario, USD Million)
Figure13.24 Prefilled Syringes Market, Distribution by Regions, 2015 - 2025 (%)
Figure 15.1 Prefilled Syringes Market: 2015, 2020 and 2025 (Units, Billions)
Figure 15.2 Prefilled Syringes Market: 2015, 2020, and 2025 (USD Billion)
Table 3.1 Drugs: From Vials to Prefilled Syringe Systems, US
Table 3.2 Classification of Prefilled Syringes
Table 3.3 Advantages of Glass as Barrel Material
Table 3.4 Prefilled Glass Syringe Recalls
Table 3.5 Advantages of Plastic Polymers as Barrel Material
Table 3.6 Pharmaceutical Filling Lines - Process Flow by Type of Prefilled Syringe
Table 3.7 Prefilled Syringe Systems Available in the Market, 2015: A Comparison, By Manufacturer
Table 3.8 Glass Prefilled Syringes Available in the Market, 2015
Table 3.9 Plastic Prefilled Syringes Available in the Market, 2015
Table 4.1 List of Add-On Safety Device Manufacturers
Table 4.2 List of Integrated Prefilled Safety Device Manufacturers
Table 5.1 Population Over 65 in the US and Selected Countries in Europe, 2010, 2015 and 2020 (%)
Table 5.2 List of Auto-injector/Pen-injector Systems - Approved in 2013-2015
Table 5.3 List of Auto-injector/Pen-injector Systems (Using Prefilled Syringes) Available in the Market
Table 6.1 Drugs Approved in Prefilled Syringes, 2013-2015
Table 6.2 List of Other Drugs Sold in Prefilled Syringes
Table 6.3 List of Some Pipeline Drugs Using Prefilled Syringe Systems,
Table 6.4 Anti-Rheumatics Sales, 2014: Distribution by Leading Drugs (USD Million, %)
Table 6.5 Anti-Rheumatics Drugs Available in Prefilled Syringes, 2015
Table 6.6 Anti-Rheumatic Drugs Available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 6.7 Multiple Sclerosis Sales, 2014: Distribution by Leading Drugs (USD Million, %)
Table 6.8 Multiple Sclerosis Drugs Available in Prefilled Syringes, 2015
Table 6.9 Multiple Sclerosis Drugs Available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 6.10 Anti-Virals Sales, 2014: Distribution by Leading Drugs (USD Million, %)
Table 6.11 Anti-virals Available in Prefilled Syringes, 2015
Table 6.12 Anti-virals Available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 6.13 Anticoagulants Sales, 2014: Distribution by Leading Drugs (USD Million, %)
Table 6.14 Anticoagulants Available in Prefilled Syringes, 2015
Table 6.15 Anticoagulants Available in Prefilled Format: Patent Expiry and Biosimilars/Generics Development
Table 6.16 Vaccines Sales, 2014: Distribution by Leading Vaccines (USD Million, %)
Table 6.17 Leading Vaccines Available in Prefilled Syringes, 2015
Table 6.18 Anti-Diabetes Market: Distribution by Leading Drugs, 2014 (USD Million, %)
Table 6.19 Anti-Diabetes Available in Prefilled Insulin Pen, 2015
Table 6.20 Anti- Diabetes Available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 6.21 Contrast Agents Available in Prefilled Syringes, 2015
Table 7.1 Drugs Marketed in Prefilled Diluent Syringes
Table 7.2 Prefilled Syringes for Lyophilised Drugs
Table 7.3 Drugs Marketed in Dual/Multi-Chamber Prefilled Syringes
Table 8.1 Gerresheimer: Features of Gx Glass Prefilled Syringe
Table 8.2 Gerresheimer: Features of ClearJect Prefilled Syringe
Table 8.3 Features of syriQ Prefilled Syringe
Table 8.4 Features of syriQInjentle Prefilled Syringe
Table 8.5 Features of TopPac Prefilled Syringe
Table 8.6 Features of EZ-Fill Prefilled Syringe
Table 8.7 West Pharmaceutical Services: Features of Daikyo CZ Prefilled Syringe
Table 8.8 Manufacturing Facilities at Various Manufacturing Sites of Vetter Pharma
Table 9.1 PFS Component Manufacturers
Table 9.2 West Pharmaceutical Services: Plungers
Table 9.3 West Pharmaceutical Services: Manufacturing of PFS Components
Table 9.4 Datwlyer: Plungers
Table 9.5 Datwlyer: Needle Shields and Tip Caps
Table 10.1 Ypsomed: Comparison of Auto-Injectors
Table 10.2 SHL: Comparison of Auto-injectors
Table 10.3 Owen Mumford: Comparison of Auto-injectors
Table 11.1 SWOT Analysis
Table 11.2 Prefilled Syringe Recalls, 2003-2015,
Table 11.3 List of Marketed/Pipeline Needleless Injection Devices
Table 12.1 Seasonal Flu Vaccines in the US, 2014-2015
Table 12.2 Domestic Prefilled Syringe Manufacturers in China: Comparison of Product Portfolio
Table 12.3 Features of WeGo Glass PFS
Table 12.4 Drugs Approved in Prefilled Syringes Format in Japan
Table 12.5 Features of Glass PFS
Table 12.6 Features of ClearJect PFS
Table 12.7 Features of Rose-Fill Glass PFS
Table 12.8 Features of Rose-Fill Plastic PFS
Table 13.1 Prefilled Syringes Price Estimate (USD per unit)
Table 13.2 Vaccines Administered Via Prefilled Syringes
Table 13.3 List of Anticoagulants and Administration Route
Table 13.4 List of Anticoagulants Sold in Prefilled Syringes
Table 13.5 List of Multiple Sclerosis Drugs and Administration Route
Table 13.6 List of Multiple Sclerosis Drugs Sold in Prefilled Syringes
Table 13.7 List of Anti-Arthritic Drugs and Administration Route
Table 13.8 List of Anti-Arthritic Drugs Sold in Prefilled Syringes
Table 13.9 List of Anti-Anaemic Drugs and Administration Route
Table 13.10 List of Anti-Anaemic Drugs Sold in Prefilled Syringes
Table 13.11 List of Other Drugs Sold in Prefilled Syringes
Table 13.12 List of Contrast Agents using Prefilled Syringes
Table 16.1 Sales of Leading Drugs Available in Prefilled Syringes, 2014 (USD Million)
Table 16.2 Humira Global Sales, 2003-2014 (USD Million)
Table16.3 Enbrel US & Canada Sales, 2002-2014 (USD Million)
Table16.4 Enbrel Outside US & Canada (EU, Japan) Sales, 2010-2014 (USD Million)
Table 16.5 Copaxone Sales, 2001-2014 (USD Million)
Table 16.6 Copaxone Unit Sales, 2000-2008: Distribution By Vials and Prefilled Syringes (Million)
Table 16.7 Becton Dickinson Medical: Sales, 2010-2014 (USD, Billion)
Table 16.8 Becton Dickinson Medical: Sales by Sub-Segments, 2014(USD Million, %)
Table 16.9 Gerresheimer: Sales, 2010-2014 (EUR, Million)
Table 16.10 Gerresheimer: Sales by Business Divisions, 2014(EUR Million, %)
Table 16.11 Gerresheimer: Sales by Region, 2011-2014 (EUR Million)
Table 16.12 Nipro Corporation: Sales, 2010-2014 (YEN Billion)
Table 16.13 Nipro Corporation: Sales by Business Divisions, FY2013/14 (YEN Billion, %)
Table 16.14 Nipro Corporation: Global Sales by Region, FY 2013/14 (YEN Billion, %)
Table 16.15 Nipro Corporation: Sales by Domestic Market, 2010-2014 (YEN Billion)
Table 16.16 SCHOTT: Sales, FY 2012/13- FY 2013/14 (EUR Billion)
Table 16.17 SCHOTT: Sales by Business Divisions, FY 2013/14 (EUR Million, %)
Table 16.18 SCHOTT: Sales by Region, FY 2013/14 (EUR Million, %)
Table 16.19 West Pharmaceutical Services: Sales, 2010-2014 (USD Million)
Table 16.20 West Pharmaceutical Services: Sales by Business Divisions, 2014 (USD Million, %)
Table 16.21 West Pharmaceutical Services: Delivery Systems Sales, 2010-2014 (USD Million)
Table 16.22 West Pharmaceutical Services: Sales by Domestic Market, 2010-2014 (USD Million)
Table 16.23 West Pharmaceutical Services: Global Sales by Region, 2014 (USD Million, %)
Table 16.24 Unilife Corporation: Sales, FY 2010/11 – FY 2013/14 (USD Million)
Table 16.25 Datwlyer Group: Sales, 2010-2014(CHF, Million)
Table 16.26 Datwlyer Group: Sales by Business Division, 2014(CHF, Million)
Table 16.27 Aptar Stelmi: Sales by Business Division, 2014(USD, Million)
Table 16.28 Ypsomed: Sales, 2010-2014 (CHF Million)
Table 16.29 Ypsomed: Sales by Business Division, FY 2014/15 (CHF Million, %)
Table 16.30 Bespak: Sales, 2010-2014 (GBP, Million)
Table 16.31 Domestic Prefilled Syringe Manufacturers in China - Annual Production Capacities, 2012 (Million Units)
Table 16.32 Shandong Weigao: Revenue from Prefilled Syringes (RMB Million), 2010-2014
Table 16.33 Shandong Weigao, 2014: Sales by Product Category (RMB Million, %)
Table 16.34 Terumo Corporation: Sales, FY 2010- FY 2014 (YEN Billion),
Table 16.35 Terumo Corporation: Sales by Business Divisions, FY 2014/15 (YEN Billion, %)
Table 16.36 Terumo Corporation: Sales by Region, FY 2014/15 (YEN Billion, %)
Table 16.37 Prefilled Syringes Price Curve, 2015 – 2025 (USD per unit)
Table 16.38 Prefilled Syringes for Vaccines, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Table 16.39 Prefilled Syringes for Vaccines, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
Table 16.40 Prefilled Syringes for Vaccines, Forecasted Number of Units, 2015 - 2025 (Optimistic Scenario, Millions)
Table 16.41 Prefilled Syringes for Vaccines, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
Table 16.42 Prefilled Syringes for Vaccines, Forecasted Sales, 2015 - 2025 (Conservative Scenario, USD Million)
Table 16.43 Prefilled Syringes for Vaccines, Forecasted Sales, 2015 - 2025 (Optimistic Scenario, USD Million)
Table 16.44 Prefilled Syringes for Anticoagulants, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Table 16.45 Prefilled Syringes for Anticoagulants, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
Table 16.46 Prefilled Syringes for Anticoagulants, ForecastedNumber of Units, 2015 - 2025 (Optimistic Scenario, Millions)
Table 16.47 Prefilled Syringes for Anticoagulants, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
Table 16.48 Prefilled Syringes for Anticoagulants, Forecasted Sales, 2015 - 2025 (Conservative Scenario, USD Million)
Table 16.49 Prefilled Syringes for Anticoagulants, Forecasted Sales, 2015 - 2025 (Optimistic Scenario, USD Million)
Table 16.50 Prefilled Syringes for Diabetes, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Table 16.51 Prefilled Syringes for Diabetes, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
Table 16.52 Prefilled Syringes for Diabetes, Forecasted Number of Units, 2015 - 2025 (Optimistic Scenario, Millions)
Table 16.53 Prefilled Syringes for Diabetes, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
Table 16.54 Prefilled Syringes for Diabetes, Forecasted Sales, 2015 - 2025 (Conservative Scenario, USD Million)
Table 16.55 Prefilled Syringes for Diabetes, Forecasted Sales, 2015 - 2025 (Optimistic Scenario, USD Million)
Table 16.56 Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Table 16.57 Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
Table 16.58 Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Number of Units, 2015 - 2025 (Optimistic Scenario, Millions)
Table 16.59 Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
Table 16.60 Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Sales, 2015 - 2025 (Conservative Scenario, USD Million)
Table 16.61 Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Sales, 2015 - 2025 (Optimistic Scenario, USD Million)
Table 16.62 Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Table 16.63 Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
Table 16.64 Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Number of Units, 2015 - 2025 (Optimistic Scenario, Millions)
Table 16.65 Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
Table 16.66 Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Sales, 2015 - 2025 (Conservative Scenario, USD Million)
Table 16.67 Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Sales, 2015 - 2025 (Optimistic Scenario, USD Million)
Table 16.68 Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Table 16.69 Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
Table 16.70 Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Number of Units, 2015 - 2025 (Optimistic Scenario, Millions)
Table 16.71 Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
Table 16.72 Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Sales, 2015 - 2025 (Conservative Scenario, USD Million)
Table 16.73 Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Sales, 2015 - 2025 (Optimistic Scenario, USD Million)
Table 16.74 Prefilled Syringes for Other Drug Classes, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Table 16.75 Prefilled Syringes for Other Drug Classes, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
Table 16.76 Prefilled Syringes for Other Drug Classes, Forecasted Number of Units, 2015 - 2025 (Optimistic Scenario, Millions)
Table 16.77 Prefilled Syringes for Other Drug Classes, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
Table 16.78 Prefilled Syringes for Other Drug Classes, Forecasted Sales, 2015 - 2025 (Conservative Scenario, USD Million)
Table 16.79 Prefilled Syringes for Other Drug Classes, Forecasted Sales, 2015 - 2025 (Optimistic Scenario, USD Million)
Table 16.80 Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Table 16.81 Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
Table 16.82 Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Number of Units, 2015 - 2025 (Optimistic Scenario, Millions)
Table 16.83 Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
Table 16.84 Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Sales, 2015 - 2025 (Conservative Scenario, USD Million)
Table 16.85 Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Sales, 2015 - 2025 (Optimistic Scenario, USD Million)
Table 16.86 Regional Prefilled Syringes, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
Table 16.87 Regional Prefilled Syringes, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
Table 16.88 Regional Prefilled Syringes, Forecasted Number of Units, 2015 - 2025 (Optimistic Scenario, Millions)
Table 16.89 Regional Prefilled Syringes, Forecasted Sales 2015 - 2025 (Base Scenario, USD Million)
Table 16.90 Regional Prefilled Syringes, Forecasted Sales 2015 - 2025 (Conservative Scenario, USD Million)
Table 16.91 Regional Prefilled Syringes, Forecasted Sales 2015 - 2025 (Optimistic Scenario, USD Million)
The following companies and organisations have been mentioned in this report
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES